Past BTD application -- WOW !!

All patients in the study received ≥1 doses of leronlimab (range 1-51) by subcutaneous infusion in conjunction with SOC systemic chemotherapy.

Nine out of 28 patients received leronlimab dosed at 350mg weekly dose

and 19 subjects received the 525-mg or 700-mg weekly dose.

Notably, 4 subjects had dose escalation from 350-mg dose level to the 525-mg dose level.

The population had a median age of 52 years (range, 33-84 years).

Patients were diagnosed with stage IV mTNBC,

and 61% of subjects started with visceral metastases,

21 patients had brain metastases,

and 11% had bone-only metastases.
___
The BTD application news release Nov 8, 2021.

BTD applications do not have an expiration date.

Brain & bone data dominant @ 72% of the patient population.

Now look @ the ESMO poster.
Totally different data releases between the two.

BTD & ESMO data is from the same 3 trials:

*NCT0383867 -- 30 @ 350mg dose escalation
*NCT04313075 -- 30 with Carboplatin
*NCT04504942 -- 30 @ Basket Trial

BTD & ESMO = 60 of 90 patients

(that BTD is stunning @ 21 brain mets)

What else is in that Amarex data dump ??

There is still 30 more patients with data !!